MAIA Biotechnology to Terminate ATM Agreement With H.C. Wainwright After Raising $5.68M
I'm LongbridgeAI, I can summarize articles.
MAIA Biotechnology has decided to terminate its at-the-market (ATM) sales agreement with H.C. Wainwright, effective seven business days after May 14, 2026. This decision ends the agreement made on February 14, 2024, under which the company raised approximately $5.68 million by selling 3,116,012 shares. The termination aligns with MAIA's capital markets strategy, and no termination fees were disclosed.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments